Loading
MI
Misonix Inc Stock: price and insider trades · United States
Misonix Inc: what insiders have been doing
Every trade that managers of Misonix Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. The past year has been quiet: not a single insider filing for Misonix Inc. The previous disclosure was published on 8 December 2021.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
7
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
7 ops. · all time
Financial data
as of FY 2021FY ended June 2021 · cache
Income statement
RevenueUS$63.7M
Gross profitUS$45.3M71% margin
Net income-US$12.5M-19.6% margin
Last declaration on 8 December 2021
Declarations7 total
1,744,017 sharesCommon StockSEC:0001493152-21-030857:0
2,136,478 sharesCommon StockSEC:0001493152-21-030853:0
276,200 sharesCommon StockSEC:0001493152-21-030845:0
319,443 sharesCommon StockSEC:0001493152-21-030849:0
1,744,017 sharesCommon StockSEC:0001493152-21-030847:0
104,500 sharesCommon StockSEC:0001493152-21-030851:0
7 of 7 declarations
About Misonix Inc
Misonix Inc. (ticker MSON) was a U.S.-listed medical technology company traded on the Nasdaq market in the United States. For investors, an important point is that Misonix no longer operates as an independent public company: it was acquired by Bioventus and became part of that group in October 2021. Historically, however, Misonix built a recognizable position in therapeutic ultrasonic technologies used in minimally invasive surgery and advanced wound care.
The company’s origins are tied to New York, where it was long based as a New York corporation with its headquarters associated with the state. Over time, Misonix developed a portfolio centered on ultrasonic medical devices designed to improve clinical outcomes, reduce surgical invasiveness, and support tissue-preserving procedures. Its best-known product families included BoneScalpel and SonaStar in the surgical segment, alongside SonicOne, TheraSkin, and Therion in wound management. These products addressed procedures in neurosurgery, spine surgery, general surgery, and advanced wound healing.
Read moreShow less
From a business-model perspective, Misonix combined capital equipment with recurring consumables, particularly in the U.S. market. Its commercialization strategy relied on direct sales in the United States, supported by commissioned agents and, internationally, by distribution partners. That structure made the company more specialized than large diversified medtech groups, but also more focused on a clear technological niche. In competitive terms, Misonix was not a broad-line device manufacturer; instead, it aimed to differentiate itself through ultrasonic precision, minimally invasive workflow benefits, and clinical utility in difficult soft-tissue and bone applications.
A key strategic milestone was the acquisition of Solsys Medical, which broadened Misonix’s addressable market by adding wound-care solutions complementary to its ultrasonic platform. That move strengthened its exposure to recurring revenue and helped expand its footprint in healing-related applications.
The most significant recent corporate event was Bioventus’ completion of the acquisition on October 29, 2021. As a result, Misonix is best viewed today as a legacy public-company name and historical securities reference, rather than an active standalone listed issuer. For French-speaking investors, Misonix remains relevant as a case study in the Health & Pharma sector: a niche U.S. Nasdaq medtech company that used ultrasonic innovation to compete in specialized surgical and wound-care markets before being absorbed into a larger platform.
